ArticleTranslational lung cancer research2025
Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While immune checkpoint inhibitors (ICIs) have significantly improved outcomes for many non-small cell lung cancer (NSCLC) patients, phase 3 trials have shown limited efficacy in programmed cell death ligand 1 (PD-L1) negative subgroups. This study aimed to evaluate the real-world effectiveness and safety of ICI-containing regimens Methods: This multicenter, retrospective study analyzed advanced or recurrent NSCLC patients treated between 2015 and 2022 in Japan. From an initial screening of 1,382 patients, we identified patients with PD-L1 negative [tumor proportion score (TPS) <1%] NSCLC. We excluded patients who received molecular targeted therapy, chemoradiotherapy, or had epidermal growth factor receptor (EGFR) mutations. Overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs) were analyzed. Results: Among the 86 eligible patients identified, 54 received ICI-containing regimens (IC group) and 32 received chemotherapy alone (C group). No significant difference in OS (C Conclusions: In this real-world study of PD-L1 negative NSCLC patients, ICI-containing regimens did not demonstrate significantly improved OS or PFS compared to chemotherapy alone. Limited efficacy in this population highlights the need for further investigation and advancement in treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.